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SARS-CoV-2; severe acute respiratory syndrome coronavirus 2; DBS, dried 
bloodspot; ELISA, Enzyme Linked Immunosorbent Assay; RBD, receptor binding 
domain; RT, room temperature; PBS-T, phosphate-buffered saline containing 0.1% 
Tween-20; SD, standard deviation; OD, optical density; PoCT, point of care testing; 
EUA, Emergency Use Authorization; QC, quality control.
Abstract
Background: Serologic assays for Severe Acute Respiratory Syndrome 
Coronavirus 2 (SARS-CoV-2) have roles in seroepidemiology, convalescent plasma-
testing, antibody durability and vaccine studies. Currently, SARS-CoV-2 serology is 
performed using serum/plasma collected by venepuncture. Dried bloodspot (DBS) 
testing offers significant advantages; as it is minimally invasive, avoids venepuncture 
with specimens being mailed to the laboratory. 
Methods: A pathway utilising a newborn screening laboratory infrastructure was 
developed using an Enzyme-Linked Immunosorbent assay (ELISA) to detect IgG 
antibodies against the receptor-binding domain (RBD) of the SARS-CoV-2 spike 
protein in DBS specimens. Paired plasma and DBS specimens from SARS-CoV-2 
antibody positive and negative subjects and PCR positive subjects were tested. DBS 
specimen stability, effect of blood volume and punch location were also evaluated.
Results: DBS from antibody-negative (n=85) and positive (n=35) subjects and PCR 
positive subjects (n=11) had a mean (SD; range) optical density (OD) of 0.14 (0.046; 
0.03-0.27), 0.98 (0.41; 0.31-1.64) and 1.12 (0.37; 0.49-1.54), respectively. An action 
value OD >0.28 correctly assigned all cases. The weighted Deming regression for 
comparison of the DBS and the plasma assay yielded: y=0.004041+1.005x, r=0.991, 
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Sy/x 0.171, n=82. Extraction efficiency of antibodies from DBS was >99%. DBS were 
stable for at least 28 days at ambient room temperature and humidity. 
Conclusions: SARS-CoV-2 IgG RBD antibodies can be reliably detected in 
DBS. DBS serological testing offers lower costs than either point of care or 
serum/plasma assays that require patient travel, phlebotomy and hospital/clinic 
resources; the development of a DBS assay may be particularly important for 
resource poor settings.
Keywords: Dried bloodspots, SARS-CoV-2, Antibodies, Enzyme Linked 
Immunoassay (ELISA), COVID-19
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Introduction
Serological testing for Severe Acute Respiratory Syndrome Coronavirus 2 
(SARS-CoV-2) is important clinically, in the selection of convalescent plasma 
donors, understanding durability of antibody responses, to assess the impact of a 
second or subsequent surge, to monitor antibody production when vaccines 
become available and in seroprevalence studies. A number of point of care tests 
(PoCT) and larger scale commercially available immunoassay platforms have 
been developed for serological assessment of SARS-CoV-2 antibodies in plasma 
/ serum.1,2 In April 2020, due to urgency and demand, the FDA issued an 
umbrella Emergency Use Authorization (EUA) for COVID-19 serologic testing, 
allowing these assays to be released without review by the FDA.2 However, this 
umbrella EUA was revoked in July 2020 and individual EUAs now have to be 
issued that meet the requisite EUA statutory criteria.3 The choice of assay and its 
performance characteristics are therefore critical to address the potential 
categories of use. However, the utility of these plasma/serum tests have not been 
fully defined, with few studies having been published using large patient cohorts.4
There is an urgent need to develop sensitive and specific cost-effective assays 
which have a high sample volume throughput. Such assays would allow 
collection of more granular information to inform modelling regionally and policy 
on lock down measures, allow testing ahead of planned hospital procedures and 
facilitate seroprevalence studies in care home residents, health and social care 
workers and other priority groups. The scalability of conventional approaches are 
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limited by the parallel requirement for a huge increase in phlebotomy workforce 
(estimated 5-10 blood venepunctures per hour per phlebotomist – at the lower 
end of the range if needing to use personal protective equipment).
Dried blood spot (DBS) specimens have been used both to screen babies for 
phenylketonuria and to monitor their dietary treatment since the 1960s. The use 
of DBS specimens to monitor patients is widely favoured due to the simplicity and 
convenience of collecting blood from a finger prick onto a filter paper collection 
device in the patient’s home and mailing the specimen directly to the laboratory 
for analysis.5 DBS collection methods have also proven useful for serology 
testing of hepatitis and HIV in resource-limited settings.6-8 Furthermore, in a 
recent cost evaluation study of the use of DBS specimen collection compared to 
conventional sampling, it was shown that DBS sampling was associated with 
significant cost reductions.9
We propose DBS testing for anti-SARS-Cov-2 antibodies using a ‘kit’ containing 
instructions on using a lancet to obtain capillary blood, a blood spot filter paper 
collection device and a return mail envelope would enable testing without an 
appointment or the need to travel to a health care facility. The costs of DBS 
serological testing are lower than either lateral flow PoCT assays or laboratory 
assays that require patient travel, phlebotomy and hospital / clinic resources, 
making the development of a DBS assay for SARS-CoV-2 antibodies 
advantageous in resource poor settings.  
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Accordingly, a scaleable and cost-effective assay protocol was developed to 
elute and detect SARS-CoV-2 receptor binding domain (RBD) specific IgG 
antibodies in DBS specimens using an ELISA based assay. The aim of this study 
was to characterise the performance of this assay protocol in DBS specimens 
using an existing national newborn screening laboratory infrastructure.
Materials and Methods
Reagents and Consumables
All chemicals, except where otherwise stated, were obtained from either Fisher 
Scientific UK (Loughborough, UK) or Sigma Aldrich (Gillingham, UK) and were of 
analytical grade. PerkinElmer 226 filter paper (PerkinElmer, Turku, Finland) was 
used for all sample collections and experimental preparations. DBS sub–punches 
were obtained using a DBS puncher (PerkinElmer, Turku, Finland) using 6 mm 
and 3.2 mm diameter punch heads. 
Test specimens
Specimens used in the assay evaluation and analysis were either anonymised 
residual samples which would otherwise have been discarded or obtained from 
participants who provided consent for additional DBS testing with Health 
Research Authority ethical approval - IRAS Project ID 284129. Patient specimens 
were classified on the basis of a positive or negative result as assessed by one of 
the following SARS-CoV-2 antibody detection methods; Abbott Diagnostics IgG, 
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PoCT (IgG/IgM-Healgen Scientific # GCCOV-402a) or Euroimmun IgG assays). 
An additional 11 DBS specimens were obtained from PCR positive cases. The 
duration from symptom onset and specimen collection was not recorded. 
Direct ELISA to detect RBD IgG antibodies
An in-house direct ELISA was performed as previously described10,11 with the 
following modifications. Maxisorp (Nunc, Loughborough, UK) 96-well plates were 
coated with RBD protein (recombinantly generated in a mammalian expression 
system, in house) at 0.5 µg/mL in bicarbonate buffer, pH 9.6 at 4°C overnight; 
wells were blocked (1 hour at room temperature (RT) with 3% w/v non-fat dried 
milk powder in phosphate-buffered saline containing 0.1% Tween-20 (PBS-T)) 
and washed in PBS-T. Dilutions of patient serum/plasma (1 in 50 in PBS-T 
containing 1% non-fat milk), were added to coated wells and incubated for 2 hr at 
RT. Wells were washed three times with PBS-T then incubated (1 hour, RT) with 
a secondary antibody (donkey anti-human IgG F(ab')₂-horseradish peroxidase 
(HRP); Jackson ImmunoResearch, # 709-036-149, Ely, UK) for 1 hour at RT. 
After washing (x3), plates were developed using O-phenylenediamine 
dihydrochloride (OPD) and the optical density (OD) measured at 492 nm. This 
assay was initially validated for the measurement of serum/plasma samples and 
then further validated for DBS eluates. The DBS manual ELISA assay was then 
transferred onto an automated platform (DSX®, Dynex Technologies).
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Assay optimisation
To optimise the conditions for the ELISA analysis of DBS specimens, we 
compared different elution buffers and DBS sub-punch size. Residual whole 
blood EDTA specimens from SARS-CoV-2 negative and positive subjects were 
applied (100µL aliquots) to filter paper. Specimens were dried over night at 
ambient temperature. Sub-punches of 6 mm and 3.2 mm diameters were taken 
from the DBS specimens, placed into 2ml 96 well plates (Waters # 186002482). 
Buffers comprising PBS-T containing non-fat milk (1-5%) or bovine serum 
albumin (0.5%) were added in varying volumes (200-500µL). The plates were 
then covered and shaken at room temperature for up to 3 hours. In addition, we 
assessed the effect of adding sodium azide and hydrogen peroxide to the eluting 
buffers to inhibit the background red cell peroxidases. Preliminary investigations 
demonstrated that incubating a 6 mm sub-punch in 300µL of PBS containing 
0.1% Tween-20 and 5% non-fat milk protein for 1 hour gave the optimum OD 
signal in eluates from positive samples and the lowest background OD signal in 
the negative samples. The protocol was aligned with the existing national 
newborn screening laboratory equipment and work flows using semi-automated 
sub-punching equipment, allowing two 96 well plates to be prepared per hour 
(DELFIA DBS Puncher, PerkinElmer), with same day elution (1 hour) and 
transfer to 96 well ELISA plates. 
 
To determine the optimal volume of buffer used to elute the antibodies from the 
DBS specimens in order to give comparable OD results to the paired plasma / 
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serum specimens (diluted 1 in 50), we calculated the volume of serum/plasma in 
a 6 mm punch. Whole blood EDTA samples (n=8) were pooled and sample 
volumes of 10, 20, 35, 50 and 100µL applied to filter paper (n=5) using a 
calibrated pipette. The diameters of the various DBS specimens were measured 
(using a magnifying ruler) and the area of the DBS was calculated (πr2) and 
plotted against the blood volume applied to the filter paper collection device 
(Figure 1). 
Recovery of SARS-CoV-2 IgG antibodies from DBS specimens was assessed 
using a series of whole blood EDTA specimens (n=7); specimens were gently 
mixed, 100µL aliquots dispensed onto filter paper, and dried over night at 
ambient temperature. Whole blood lysates were prepared from the same 
samples by subjecting a 200µL aliquot of whole blood to an overnight freeze (-
20°) to lyse the red cells. The remaining portion of the specimen was then 
centrifuged, the plasma removed and stored at 4°C prior to analysis. DBS 
specimens were punched in duplicate and analysed in a single analytical batch 
with paired plasma and whole blood lysate specimens. 
Assay precision was assessed using antibody-negative quality control (QC) and 
antibody-positive QC specimens, generated by pooling residual anonymised 
EDTA whole blood specimens from antibody positive and negative subjects. 
Aliquots (100µL) of whole blood were dispensed onto filter paper and dried over-
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night at ambient temperature. DBS QC material was then stored desiccated at -
20°C.
The utility of 5 commercially available SARS-CoV-2 antibody assays for DBS 
eluate testing were also explored; Siemens total antibody (IgG/A/M), Siemens 
IgG (Siemens, Frimley, UK), Ortho Diagnostics IgG (Ortho Clinical Diagnostics, 
Bridgend, UK), Abbott Diagnostics IgG (Abbott, Maidenhead, UK) and Roche IgG 
(Roche Diagnostics, Burgess Hill, UK). The capacity of each assay to detect 
SARS-CoV-2 antibodies in DBS specimens using our elution protocol was 
assessed.
Variability in DBS specimen collection and sub-punch location can affect analyte 
results. To explore this, the effect of blood sample volume and non-homogeneity 
in the DBS specimens on the measurement of SARS-CoV-2 IgG antibodies was 
assessed by preparing pooled residual EDTA blood samples from antibody 
positive subjects (n=8). Aliquots of 20, 35, 50 and 100µL of the pooled blood 
were dispensed onto filter paper and dried over-night at ambient temperature. To 
examine the effect of double layering of blood onto the filter paper collection 
device, 35µL of whole blood was applied to the filter paper and then a further 
35µL was re-applied immediately. Five sub-punches from the different DBS size 
categories were analysed by punching once from the centre and twice from the 
edge. Only central punches were taken from the 10µL and 35µL specimens (area 
too small for >1 punch). 
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Analysis of paired plasma and DBS specimens
EDTA samples were collected as part of routine Hospital staff SARS-CoV-2 
antibody testing. EDTA samples were gently mixed and 100µL of blood was 
applied onto the filter paper using a pipette. The remainder of the EDTA blood 
specimen was centrifuged and the plasma removed for analysis using the in 
house ELISA. Contemporaneous serum/plasma samples were also collected and 
analysed using the lateral flow PoCT device (IgG/IgM-Healgen Scientific, 
Houston, USA).
Assessment of SARS-CoV-2 antibody stability in DBS specimens
Residual whole blood EDTA specimens from SARS-CoV-2 antibody positive 
subjects (n=12) were pooled. Replicate DBS specimens were prepared by applying 
100µL volumes to filter paper, dried overnight at ambient temperature and humidity. 
Specimens were then stored either at ambient humidity, within a sealed foil bag 
containing a desiccant (low humidity) or in a sealed box containing wet paper towels 
(high humidity, at the following temperatures; -20°C, +4°C, room temperature 
(~25°C), and 40°C for between 1 and 28 days. At various time intervals (Table 1), 
samples were removed and stored desiccated in sealed foil bags at -20°C prior to 
analysis in duplicate at the end of the study. Results were calculated as the % 
residual OD, using DBS specimens that were stored desiccated at -20°C, during the 
study period as the control (i.e. 100%) and analysed alongside those specimens 
subjected to the various heat and humidity conditions.
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Statistical Analysis
Analysis of differences between groups was carried out using a Kruskal-Wallis 
test with a Tukey's Multiple Comparison Test. The action value OD for positivity 
was calculated for DBS samples as the mean+3SD of the results obtained from 
antibody negative subjects. All analyses were performed using SPSS v21.
Results 
Relationship of DBS area to blood volume
The relationship between DBS area and volume was linear (r=0.998) and the 
gradient of the slope was y=2.2016x (Figure 1). Thus a 6 mm sub-punch (area 
28.26 mm2) corresponds to a whole blood volume of 12.84µL and approximately 
5.8 to 6.4µL of plasma/serum (assuming an average haematocrit of 45-50% in 
adult subjects). Using an elution buffer volume of 300µL for a single 6 mm sub-
punch, it is estimated that the serum component is diluted by a factor of 1 in 47 to 
1 in 51, which is comparable with the optimal dilution for plasma / serum samples 
in the assay.
Assay performance
For antibody recovery studies; the mean (SD & range) OD responses for paired 
DBS, plasma and whole blood lysates (n=7) was 1.39 (0.27; 0.97 – 1.64), 1.29 
(0.34; 0.77 – 1.65) & 1.27 (0.33; 0.74 – 1.6) respectively. The mean (SD; range) 
extraction efficiency (%) of plasma antibodies from DBS specimens using the 
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optimized buffer was 109 (10.6; 99-125). The intra-assay (n=10) and inter-assay 
(n=8) CVs for the antibodies in the QC specimens, respectively, were as follows: 
negative (0.22 OD), 8.7% and 12.6%, and positive (1.58 OD) 3.3% and 10.6%.
Analysis of DBS from SARS-CoV-2 antibody positive and negative 
subjects.
DBS specimens from SARS-CoV-2 antibody negative subjects (n=85) had a 
mean (SD; range) OD of 0.14 (0.046; 0.03-0.27), while SARS-CoV-2 antibody 
positive cases (n=35) had a mean (range) OD of 0.98 (0.41; 0.31-1.64). Eleven 
subjects who tested positive for COVID-19 by PCR had a mean OD response of 
1.1 (0.37; 0.49-1.54) (Figure 2). The action value OD for the SARS-CoV-2 
antibody positive DBS samples was calculated as the mean+3SD of the results 
obtained from antibody negative subjects (OD>0.28) and correctly classified all 
cases (Figure 2). 
A Bland-Altman plot of the absolute difference between SARS-CoV-2 IgG 
antibodies in plasma specimens analysed by the in house ELISA and in paired 
DBS specimen eluates analysed by the DBS ELISA, demonstrated a mean bias 
between the two methods of -0.008 OD (Figure 3). Deming regression analysis 
(Analyze-It, Leeds, UK) revealed an agreement between the assays for SARS-
CoV-2 IgG antibodies in the paired plasma and DBS specimens, which 
demonstrated a slope (95%CI) of the regression line of 1.005 (0.9573 to 1.053), 
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intercept (95%CI) of 0.004 (-0.007 to 0.015), an Sy/x of 0.171 and a correlation 
coefficient (r) of 0.991. Serum samples analysed using the Healgen Scientific 
PoCT lateral flow device (detects antibodies to both the viral spike and 
nucleocapsid proteins) and the paired DBS eluates analysed using the in house 
ELISA gave concordant results (Figure 4).
Comparison of DBS eluates analysed by in the house ELISA vs commercial 
serologic assays
High background signals were obtained using DBS eluates on the Ortho 
Diagnostics IgG assay and both the Siemens total antibody and IgG assays; as a 
consequence, these assays were unable to distinguish between SARS-CoV-2 
antibody positive and negative samples (data not shown). The Roche assay gave 
adequate separation in results between the positive and negative QC samples. 
However, in a subset of DBS specimens from SARS-CoV-2 antibody negative 
(n=44) and positive cases (n=25), the Roche assay was not sensitive enough to 
detect antibodies in the majority of the DBS eluates from antibody positive cases 
(Figure 5).
Effect of DBS size and punch location
OD values were significantly affected by DBS size and punch location (P=0.002). 
Smaller bloodspot volumes (20 µL and 35 µL) produced significantly lower OD 
values (10% and 16% respectively) when compared to the 100µL DBS with a 
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peripheral punch (P<0.05). Peripheral punches from layered specimens (double 
spotted 35µL DBS) produced significantly higher OD values than those obtained 
from 20µL, 35µL and 50µL central punches (11%, 17% and 11% respectively) 
(P<0.05). The OD values obtained using a peripheral punch from the 100µL and 
the double spotted 35µL DBS specimens were 11% and 13.0% higher 
(respectively) than those obtained from a 50µL central punch (P<0.05). A positive 
bias was observed for the antibody ODs obtained using a peripheral punch vs a 
central punch, however, this did not reach statistical significance.
DBS specimen stability studies
Both humidity and temperature affected the stability of the antibodies in DBS 
specimens (Table 1). At room temperature with low or ambient humidity, 
antibodies were stable for at least 28 days. The same was observed at +4°C and 
-20°C with both ambient and low humidity conditions. Specimens stored at +40°C 
with low or ambient humidity were stable for up to 7 days. However, antibodies 
degraded rapidly when stored at +40°C and at high humidity, with decreases of 
35%, 55% and 73% being observed at day 3, 14 and 28, respectively. 
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Discussion
In this work we describe the systematic optimisation of the elution of SARS-CoV-
2 RBD IgG antibodies from DBS specimens for analysis using an optimised in 
house high-throughput ELISA assay. Our protocol builds upon a proven 
infrastructure of newborn blood spot screening testing and allows the cost-
effective use of equipment and expertise that currently exist in these laboratories.
Several studies have recently examined the utility of DBS SARS-CoV-2 antibody 
testing.12-17 However, many of these studies suffer from small sample sizes12, 14, 15   
or use sample punching / sample extraction procedures that do not make the 
assay amenable for rapid high throughput testing.12, 15, 16 Furthermore, none of 
these studies have linked testing with the established newborn DBS screening 
laboratory infrastructure.
The development of high throughput DBS anti-SARS-CoV-2 antibody testing 
which links with the newborn DBS screening laboratories is of particular value for 
three main reasons. Firstly; healthcare workers such as phlebotomists, nurses or 
doctors are not required to take blood, reducing the risk of possible COVID-19 
transmission to or from healthcare workers, and the sample can easily be taken 
in the home; this is particularly important for those vulnerable groups who may be 
shielding. Secondly, the method does not require blood collection tubes or 
syringes, and given our specimen stability findings, the DBS can be sent via the 
mail / postal system, enabling testing at distance, where blood collection 
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resources are limited, and at scale. DBS specimens pose a minimal biohazard 
risk due to the fact that viruses on the cotton filter paper matrix loose infectivity 
upon drying and so are not readily transmissible.18-20 The send-in approach 
automatically links the testing to centralized laboratory platforms, which feed 
results directly into existing electronic pathology systems, which negates the 
need for further software development and additional IT infrastructure resource 
when using PoCT lateral flow devices at home. Thirdly; the cost of collecting the 
specimen is low, which becomes increasingly important in scenarios where many 
specimens are needed (e.g. when testing specific population cohorts such as 
students, school teachers, nursing home residents or groups of healthcare 
workers in seroprevalence studies) as the cost of obtaining the specimen is 
significantly greater than the cost of the test itself. 
The DBS OD values obtained in our assay for SARS-CoV-2 antibody negative 
and positive subjects were comparable to the plasma OD values observed in our 
assay and in previous studies on which our ELISA is based.10, 11 The action value 
for positivity (0.28) correctly classified all cases. The OD values observed in the 
antibody and PCR positive cases demonstrated complete separation from the 
antibody negative subjects. However, further work is required to validate the OD 
cut-off for positivity, using paired DBS and plasma/serum specimens from a 
larger number of mild and severe COVID-19 patients, with confirmed positive 
PCR test results and to assess the duration from symptom onset on antibody 
concentrations. 
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In addition, we demonstrated good agreement between the OD values obtained 
for paired DBS and plasma specimens, confirming excellent recovery of the 
antibodies from DBS specimens. This finding confirms that of Morley and 
colleagues, using a similar ELISA format.16 To further characterise the 
performance of our DBS assay, we compared the OD values obtained for DBS 
specimens analysed using the ELISA to the results from paired serum results 
obtained using the Healgen Scientific PoCT (IgG &IgM) lateral flow device 
(detects antibodies to both the spike and nucleocapsid proteins). The results 
demonstrated good concordance between paired specimens.
Our assay detects the RBD of the virus spike protein whereas many of the 
commercial assays detect the nucleocapsid protein. Current assays are evolving 
with an emphasis on those assessing antibodies to the RBD protein as these 
appear to correlate better with neutralising antibodies and may be more sensitive 
in mild disease settings.21 The open nature of ELISA assays allows for 
optimisation to different sample types (e.g. saliva), which is more challenging 
when using the ‘black box’ commercial assays. It also permits further flexibility in 
evolution of testing e.g. SARS-CoV-2 IgA from serum / plasma or saliva22 or the 
detection of antibodies to the nucleocapsid, RBD and spike proteins in a single 
assay.17 
Furthermore, assay performance will be improved when certified reference 
material for anti-SARS-CoV-2 antibody calibrators become available and enable 
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standardisation of quantitative results. Indeed, efforts are currently being made to 
develop calibrator material for assay standardisation.
The volume of blood applied to the filter paper collection device, and the location 
of the sub-punch (peripheral vs central) can have a significant impact on the 
result obtained for certain metabolites.23 We examined the impact of DBS 
specimen volume and punch location on antibody OD responses and 
demonstrated that these factors have a small but significant effect on the results 
obtained. These findings are consistent with previous reports for biomarkers 
quantified in DBS specimens, and highlights the importance of obtaining good 
quality specimens for analysis to ensure accurate test results.23-25 
 
DBS specimens need to be transported to the laboratory (usually via the mail 
service) for analysis and during this process (2-5 days) specimens can be 
exposed to extreme environmental conditions. Assay protocols for plasma / 
serum SARS-CoV-2 antibodies recommend that samples should be heat treated 
(60 min at 56°C) to inactivate the virus.10, 11 It has been shown that heat treated 
samples gave comparable OD values to that of non-heat treated samples10 (and 
in house data; not shown) demonstrating that COVID-19 antibodies are relatively 
stable. However, no previous studies have assessed the long term stability of 
SARS-CoV-2 IgG antibodies in DBS specimens at various temperatures and 
humidity. We have shown that antibodies in DBS specimens are stable at 
ambient and lower temperatures. However, antibodies degraded rapidly when 
stored at +40°C with high humidity. Our findings are comparable to those found 
Page 21 of 35
Annals of Clinical Biochemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Author Accepted Manuscript
Peer Review
 Version
21
in studies assessing the stability of HIV antibodies in DBS specimens at various 
temperatures and humidty.26 While these data give confidence that standard 
mailing in temperate climates will have little impact on DBS measurements, we 
recommend that DBS specimens should be protected from moisture as much as 
possible and should be stored desiccated for the short term at 4°C, prior to 
analysis in the laboratory. On the basis of our findings it is likely that long-term 
stability can be achieved using desiccants and storage temperatures of -20°C or 
lower. An incidental finding during the stability study, was the observation that 
those sub-punches taken from specimens subjected to both high humidity and 
temperature, remain dark red, following the elution step, whereas those taken 
from appropriately stored specimens turn from red to white following the elution 
step. Therefore, the quality of the specimen received for analysis (and the validity 
of the result) can be assessed visually following the elution step and those 
samples where the blood has not fully eluted from the sub-punch, should be 
rejected.
In conclusion, this study demonstrates the utility of DBS specimen collection for 
SARS-CoV-2 antibody detection using an ELISA assay as a cost-effective and 
efficient approach for large scale antibody testing and may be particularly 
important for resource poor settings.
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Table 1 – Stability of COVID-19 antibodies under various conditions of 
temperature and humidity.
Length of storage (days)
Storage Conditions 0 1 3 7 14 21 28
-20°C, Low Humidity 100 93 100 103 101 97 97
-20°C, Ambient Humidity 100 107 109 99 109 97 90
+4°C, Low Humidity 100 99 102 104 105 92 102
+4°C,  Ambient Humidity 100 105 98 104 97 92 92
RT, Low Humidity 100 107 103 103 99 96 102
RT, Ambient Humidity 100 99 104 103 102 97 93
RT, High Humidity 100 97 102 102 91 92 94
40°C, Low Humidity 100 108 101 96 95 90 91
40°C, Ambient Humidity 100 107 97 96 94 90 97
40°C, High Humidity 100 81 65 57 45 29 27
DBS specimens were stored at the various temperatures and conditions. At the 
various time intervals, samples were removed and stored desiccated in sealed foil 
bags at -20°C prior to analysis in duplicate at the end of the study. Results shown 
are % residual OD, using DBS specimens that were stored desiccated at -20°C, 
during the study period as the control (i.e. 100%) and analysed alongside those 
specimens subjected to the various heat and humidity conditions. The mean (SD) 
OD for the 100% control was 1.52 (0.14).
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Figure Legends
Figure 1 (A) Effect of sample volume on blood spot diameter. A whole blood 
EDTA sample was applied to filter paper collection devices at the 
volumes shown. Sub-punches (6 mm) were taken from the central 
and peripheral locations (B) Relationship between the volume of 
blood applied to filter paper collection device and the DBS area. 
Results are the mean of 5 replicates.
Figure 2 Performance of the DBS SARS-CoV-2 IgG ELISA for specimens 
from SARS-CoV-2 negative antibody subjects (n=85), SARS-CoV-2 
antibody positive subjects (n=35) and SARS-CoV-2 PCR positive 
subjects (n=11). The dotted line represents the action value for 
positivity on the DBS ELISA (OD >0.28).
Figure 3 Bland-Altman plot showing the absolute difference for SARS-CoV-2 
IgG antibody OD’s between the plasma specimens analysed by the 
in house ELISA and in paired DBS specimen eluates analysed by 
the in house ELISA. The solid horizontal line denotes the mean bias 
between the two methods (-0.008 OD). The dashed horizontal lines 
indicates the 95% limits of agreement. The dashed vertical line 
denotes the action value for positivity on the DBS ELISA (>0.28). 
The weighted Deming plot yielded a slope of 1.005 (95%CI; 0.9573 
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to 1.053), intercept of 0.004, (95%CI; -0.007 to 0.015), an Sy/x of 
0.171 and a correlation coefficient (r) of 0.991. Paired plasma and 
DBS specimens used were from SARS-CoV-2 negative subjects 
(n=47) and positive antibody subjects (n=35).
Figure 4 Concordance between the DBS ELISA and the Healgen Scientific 
PoCT (IgG/IgM) lateral flow device using paired DBS and serum 
specim ns from SARS-CoV-2 negative subjects (n=47) and 
positive antibody subjects (n=28). The dotted line represents the 
action value for positivity on the DBS ELISA (OD >0.28).
Figure 5 Concordance between the DBS ELISA and Roche commercial IgG 
serologic assay using DBS eluates using specimens from SARS-
CoV-2 negative subjects (n=44) and positive antibody subjects 
(n=25). The dotted line represents the action value for positivity on 
the DBS ELISA (OD >0.28).
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